BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gisbert JP, Chaparro M. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Journal of Crohn's and Colitis 2020;14:694-709. [DOI: 10.1093/ecco-jcc/jjz195] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 12.7] [Reference Citation Analysis]
Number Citing Articles
1 Park SH, Park SH. Personalized medicine in inflammatory bowel disease: Perspectives on Asia. J Gastroenterol Hepatol 2022. [PMID: 35726657 DOI: 10.1111/jgh.15919] [Reference Citation Analysis]
2 Juillerat P, Grueber MM, Ruetsch R, Santi G, Vuillèmoz M, Michetti P. Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom? Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100104] [Reference Citation Analysis]
3 Bertani L, Barberio B, Fornili M, Antonioli L, Zanzi F, Casadei C, Benvenuti L, Facchin S, D'antongiovanni V, Lorenzon G, Ceccarelli L, Baglietto L, de Bortoli N, Bellini M, Costa F, Savarino EV, Fornai M. Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.03.008] [Reference Citation Analysis]
4 Dal Buono A, Roda G, Argollo M, Zacharopoulou E, Peyrin-Biroulet L, Danese S. Treat to target or 'treat to clear' in inflammatory bowel diseases: one step further? Expert Rev Gastroenterol Hepatol 2020;14:807-17. [PMID: 32762582 DOI: 10.1080/17474124.2020.1804361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Caviglia GP, Ribaldone DG, Nicolosi A, Pellicano R. Cytokines and Biologic Therapy in Patients with Inflammatory Bowel Diseases. Gastroenterology Insights 2021;12:443-5. [DOI: 10.3390/gastroent12040042] [Reference Citation Analysis]
6 Xu L, Shen J, Zheng Q. Development of a clinical model to predict secondary non-response of infliximab treatment in Crohn's disease. Int J Colorectal Dis 2020;35:2019-26. [PMID: 32577870 DOI: 10.1007/s00384-020-03679-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Lin L, Wang Y, Lu X, Wang T, Li Q, Wang R, Wu J, Xu J, Du J. The Inflammatory Factor SNP May Serve as a Promising Biomarker for Acitretin to Alleviate Secondary Failure of Response to TNF-a Monoclonal Antibodies in Psoriasis. Front Pharmacol 2022;13:937490. [DOI: 10.3389/fphar.2022.937490] [Reference Citation Analysis]
8 Ayyar KK, Moss AC. Exosomes in Intestinal Inflammation. Front Pharmacol 2021;12:658505. [PMID: 34177577 DOI: 10.3389/fphar.2021.658505] [Reference Citation Analysis]
9 Iliopoulou L, Kollias G. Harnessing murine models of Crohn's disease ileitis to advance concepts of pathophysiology and treatment. Mucosal Immunol 2021. [PMID: 34316007 DOI: 10.1038/s41385-021-00433-3] [Reference Citation Analysis]
10 Chaparro M, Garre A, Mesonero F, Rodríguez C, Barreiro-de Acosta M, Martínez-cadilla J, Arroyo MT, Manceñido N, Sierra-ausín M, Vera-mendoza I, Casanova MJ, Nos P, González-muñoza C, Martínez T, Boscá-watts M, Calafat M, Busquets D, Girona E, Llaó J, Martín-arranz MD, Piqueras M, Ramos L, Surís G, Bermejo F, Carbajo AY, Casas-deza D, Fernández-clotet A, García MJ, Ginard D, Gutiérrez-casbas A, Hernández L, Lucendo AJ, Márquez L, Merino-ochoa O, Rancel FJ, Taxonera C, López Sanromán A, Rubio S, Domènech E, Gisbert JP. Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry. Journal of Crohn's and Colitis 2021;15:35-42. [DOI: 10.1093/ecco-jcc/jjaa145] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Chen G, Wang F, Nie M, Zhang H, Zhang H, Zhao Y. Roe-inspired stem cell microcapsules for inflammatory bowel disease treatment. Proc Natl Acad Sci U S A 2021;118:e2112704118. [PMID: 34686606 DOI: 10.1073/pnas.2112704118] [Reference Citation Analysis]
12 Bermejo F, Jiménez L, Algaba A, Vela M, Bastida G, Merino O, López-García A, Melcarne L, Rodríguez-Lago I, de la Maza S, Bouhmidi A, Barreiro-de Acosta M, López-Serrano P, Carrillo-Palau M, Mesonero F, Bonillo D, Granja A, Guerra I. Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy. Inflamm Bowel Dis 2021:izab015. [PMID: 33528018 DOI: 10.1093/ibd/izab015] [Reference Citation Analysis]
13 Larsen MD, Nørgård BM, Kjeldsen J. Does Disease Activity After Induction Treatment With Biologics Predict Short-Term Outcome in Crohn's Disease and Ulcerative Colitis? Inflamm Bowel Dis 2022:izab331. [PMID: 34977919 DOI: 10.1093/ibd/izab331] [Reference Citation Analysis]
14 Cui G, Florholmen J, Goll R. Could Mucosal TNF Transcript as a Biomarker Candidate Help Optimize Anti-TNF Biological Therapy in Patients With Ulcerative Colitis? Front Immunol 2022;13:881112. [PMID: 35663996 DOI: 10.3389/fimmu.2022.881112] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Baldan-Martin M, Chaparro M, Gisbert JP. Tissue Proteomic Approaches to Understand the Pathogenesis of Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27:1184-200. [PMID: 33529308 DOI: 10.1093/ibd/izaa352] [Reference Citation Analysis]
16 Gisbert JP, Chaparro M. Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)? J Clin Med 2021;10:5318. [PMID: 34830595 DOI: 10.3390/jcm10225318] [Reference Citation Analysis]
17 Han ZM, Chen BX, Zhou Q, Liu HB, Xu PC, Zhi FC. Predictors of infliximab-induced deep remission in treatment-naïve patients with isolated small bowel Crohn's disease. Scand J Gastroenterol 2021;56:1422-6. [PMID: 34461786 DOI: 10.1080/00365521.2021.1971759] [Reference Citation Analysis]
18 Sakaram S, Hasin-Brumshtein Y, Khatri P, He YD, Sweeney TE. A Multi-mRNA Prognostic Signature for Anti-TNFα Therapy Response in Patients with Inflammatory Bowel Disease. Diagnostics (Basel) 2021;11:1902. [PMID: 34679598 DOI: 10.3390/diagnostics11101902] [Reference Citation Analysis]
19 Hashash JG, Mourad FH. Positioning biologics in the management of moderate to severe Crohn's disease. Curr Opin Gastroenterol 2021;37:351-6. [PMID: 33731644 DOI: 10.1097/MOG.0000000000000735] [Reference Citation Analysis]
20 Kim KU, Kim J, Kim WH, Min H, Choi CH. Treatments of inflammatory bowel disease toward personalized medicine. Arch Pharm Res 2021;44:293-309. [PMID: 33763844 DOI: 10.1007/s12272-021-01318-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Ye XQ, Cai J, Yu Q, Cao XC, Chen Y, Rao MX, Chen BL, He Y, Zeng ZR, Chen H, Lin YM, Cao Q, Chen MH, Zhang SH. Nomogram to predict primary non-response to infliximab in patients with Crohn's disease: a multicenter study. Gastroenterol Rep (Oxf) 2021;9:329-38. [PMID: 34567565 DOI: 10.1093/gastro/goaa069] [Reference Citation Analysis]
22 Park J, Chun J, Yoon H, Cheon JH. Feasibility of a Clinical Decision Support Tool for Ustekinumab to Predict Clinical Remission and Relapse in Patients With Crohn's Disease: A Multicenter Observational Study. Inflamm Bowel Dis 2022:izac105. [PMID: 35670522 DOI: 10.1093/ibd/izac105] [Reference Citation Analysis]
23 Gilardi D, Gabbiadini R, Allocca M, Correale C, Fiorino G, Furfaro F, Zilli A, Peyrin-biroulet L, Danese S. PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD. Expert Review of Gastroenterology & Hepatology 2020;14:797-806. [DOI: 10.1080/17474124.2020.1785868] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Salvador-Martín S, Melgarejo-Ortuño A, López-Fernández LA. Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease. Pharmaceutics 2021;13:1786. [PMID: 34834201 DOI: 10.3390/pharmaceutics13111786] [Reference Citation Analysis]
25 Atreya R, Neurath MF, Siegmund B. Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF? Front Med (Lausanne) 2020;7:517. [PMID: 32984386 DOI: 10.3389/fmed.2020.00517] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
26 Li L, Chen R, Zhang Y, Zhou G, Chen B, Zeng Z, Chen M, Zhang S. A Novel Model Based on Serum Biomarkers to Predict Primary Non-Response to Infliximab in Crohn's Disease. Front Immunol 2021;12:646673. [PMID: 34367126 DOI: 10.3389/fimmu.2021.646673] [Reference Citation Analysis]
27 Garcia-Romero R, Martinez de Zabarte Fernandez JM, Pujol-Muncunill G, Donat-Aliaga E, Segarra-Cantón O, Irastorza-Terradillos I, Medina-Benitez E, Ruiz-Hernández CJ, Carrillo-Palau M, Ros-Arnal I, Rodriguez-Martínez A, Escartin-Madurga L, Gutiérrez-Junquera C, Vicente-Santamaría S, Velasco Rodriguez-Belvis M, Fernández-Fernández S, Alberto-Alonso JR, Montraveta M, Torres-Peral R, Navalon-Rubio M, Navas-López VM, Martin de Carpi J. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study. Eur J Pediatr 2021;180:3029-38. [PMID: 33880650 DOI: 10.1007/s00431-021-04063-6] [Reference Citation Analysis]
28 Iborra M, Beltrán B, Fernández-Clotet A, Iglesias-Flores E, Navarro P, Rivero M, Gutiérrez A, Sierra-Ausin M, Mesonero F, Ferreiro-Iglesias R, Hinojosa J, Calvet X, Sicilia B, González-Muñoza C, Antolín B, González-Vivo M, Carbajo AY, García-López S, Martín-Cardona A, Surís G, Martin-Arranz MD, de Francisco R, Cañete F, Domènech E, Nos P; GETECCU group (Grupo Español de trabajo de Enfermedades de Crohn y Colitis Ulcerosa). Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry. Aliment Pharmacol Ther 2020;52:1017-30. [PMID: 32770851 DOI: 10.1111/apt.15958] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
29 Cui G, Fan Q, Li Z, Goll R, Florholmen J. Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers. EBioMedicine 2021;66:103329. [PMID: 33862588 DOI: 10.1016/j.ebiom.2021.103329] [Reference Citation Analysis]
30 Liefferinckx C, Bottieau J, Toubeau JF, Thomas D, Rahier JF, Louis E, Baert F, Dewint P, Pouillon L, Lambrecht G, Vallée F, Vermeire S, Bossuyt P, Franchimont D. Collecting New Peak and Intermediate Infliximab Levels to Predict Remission in Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021:izab042. [PMID: 33783494 DOI: 10.1093/ibd/izab042] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 D'Amico F, Danese S, Peyrin-Biroulet L. Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins? Expert Opin Biol Ther 2020;20:353-61. [PMID: 31951748 DOI: 10.1080/14712598.2020.1717465] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
32 Caminero A, Pinto-Sanchez MI. Host immune interactions in chronic inflammatory gastrointestinal conditions. Curr Opin Gastroenterol 2020;36:479-84. [PMID: 32868507 DOI: 10.1097/MOG.0000000000000673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Fernández-Tomé S, Ortega Moreno L, Chaparro M, Gisbert JP. Gut Microbiota and Dietary Factors as Modulators of the Mucus Layer in Inflammatory Bowel Disease. Int J Mol Sci 2021;22:10224. [PMID: 34638564 DOI: 10.3390/ijms221910224] [Reference Citation Analysis]
34 Moreno LO, Fernández-tomé S, Abalo R. Biological Treatments in Inflammatory Bowel Disease: A Complex Mix of Mechanisms and Actions. Biologics 2021;1:189-210. [DOI: 10.3390/biologics1020012] [Reference Citation Analysis]
35 Wu Y, Wang Z, Xing M, Li B, Liu Z, Du P, Yang H, Wang X. The Specific Changes of Urine Raman Spectra Can Serve as Novel Diagnostic Tools for Disease Characteristics in Patients with Crohn’s Disease. JIR 2022;Volume 15:897-910. [DOI: 10.2147/jir.s341871] [Reference Citation Analysis]
36 Franzin M, Stefančič K, Lucafò M, Decorti G, Stocco G. Microbiota and Drug Response in Inflammatory Bowel Disease. Pathogens 2021;10:211. [PMID: 33669168 DOI: 10.3390/pathogens10020211] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
37 Lerang F, Holst R, Henriksen M, Wåhlberg H, Jelsness-jørgensen L. Antitumour necrosis factor alpha treatment in Crohn’s disease: long-term efficacy, side effects and need for surgery. Scandinavian Journal of Gastroenterology. [DOI: 10.1080/00365521.2022.2042592] [Reference Citation Analysis]
38 Oh SJ, Shin GY, Soh H, Lee JG, Im JP, Eun CS, Lee KM, Park DI, Han DS, Kim HJ, Lee CK. Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis. Intest Res 2021;19:323-31. [PMID: 32806875 DOI: 10.5217/ir.2020.00039] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Atreya R, Siegmund B. Location is important: differentiation between ileal and colonic Crohn's disease. Nat Rev Gastroenterol Hepatol 2021;18:544-58. [PMID: 33712743 DOI: 10.1038/s41575-021-00424-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
40 Privitera G, Pugliese D, Rapaccini GL, Gasbarrini A, Armuzzi A, Guidi L. Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. J Clin Med 2021;10:853. [PMID: 33669579 DOI: 10.3390/jcm10040853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Zhou Z, Zhang Y, Pan Y, Yang X, Li L, Gao C, He C. A Novel Neutrophil-Based Biomarker to Monitor Disease Activity and Predict Response to Infliximab Therapy in Patients With Ulcerative Colitis. Front Med (Lausanne) 2022;9:872831. [PMID: 35572985 DOI: 10.3389/fmed.2022.872831] [Reference Citation Analysis]
42 Scarozza P, Marafini I, Laudisi F, Troncone E, Schmitt H, Lenti MV, Costa S, Rocchetti I, De Cristofaro E, Salvatori S, Frezzati L, Di Sabatino A, Atreya R, Neurath MF, Calabrese E, Monteleone G. Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab. J Clin Med 2020;9:E385. [PMID: 32024071 DOI: 10.3390/jcm9020385] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Yueying C, Jing F, Tian Y, Yuqi Q, Jun S. Bioelectrical impedance analysis-based nomogram construction for predicting secondary loss of response to infliximab in bio-naïve Crohn's disease patients. Biomed Pharmacother 2021;142:112076. [PMID: 34449314 DOI: 10.1016/j.biopha.2021.112076] [Reference Citation Analysis]
44 D'Amico F, Fiorino G, Furfaro F, Allocca M, Roda G, Loy L, Zilli A, Solitano V, Peyrin-Biroulet L, Danese S. Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach. Expert Rev Gastroenterol Hepatol 2020;14:765-73. [PMID: 32427002 DOI: 10.1080/17474124.2020.1772057] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Gutiérrez A, Rodríguez-Lago I. How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data. Front Med (Lausanne) 2021;8:640813. [PMID: 33585530 DOI: 10.3389/fmed.2021.640813] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Aldars-García L, Gisbert JP, Chaparro M. Metabolomics Insights into Inflammatory Bowel Disease: A Comprehensive Review. Pharmaceuticals (Basel) 2021;14:1190. [PMID: 34832973 DOI: 10.3390/ph14111190] [Reference Citation Analysis]
47 Nie K, Zhang C, Deng M, Luo W, Ma K, Xu J, Wu X, Yang Y, Wang X. A Series of Genes for Predicting Responses to Anti-Tumor Necrosis Factor α Therapy in Crohn's Disease. Front Pharmacol 2022;13:870796. [PMID: 35517818 DOI: 10.3389/fphar.2022.870796] [Reference Citation Analysis]
48 Pagnini C, Cominelli F. Tumor Necrosis Factor's Pathway in Crohn's Disease: Potential for Intervention. Int J Mol Sci 2021;22:10273. [PMID: 34638616 DOI: 10.3390/ijms221910273] [Reference Citation Analysis]
49 Pierre N, Salée C, Vieujean S, Bequet E, Merli AM, Siegmund B, Meuwis MA, Louis E. Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology. Aliment Pharmacol Ther 2021;54:779-91. [PMID: 34297423 DOI: 10.1111/apt.16536] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Giráldez-Montero JM, Gonzalez-Lopez J, Campos-Toimil M, Lamas-Díaz MJ. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease: Limits and improvements. Br J Clin Pharmacol 2021;87:2216-27. [PMID: 33197071 DOI: 10.1111/bcp.14654] [Reference Citation Analysis]
51 Kono T, Maejima T, Ono Y, Ito T, Furukawa S, Nishiyama M, Yamamoto M, Sugitani A, Karasaki H, Mizukami Y, Maemoto A. Distinct effects of TU-100 (daikenchuto) on long-lasting dysbiosis in the small intestine in patients with colorectal cancer and inflammatory bowel disease. Gene 2022;820:146266. [PMID: 35134471 DOI: 10.1016/j.gene.2022.146266] [Reference Citation Analysis]
52 Nishioka K, Ogino H, Chinen T, Ihara E, Tanaka Y, Nakamura K, Ogawa Y. Mucosal IL23A expression predicts the response to Ustekinumab in inflammatory bowel disease. J Gastroenterol 2021;56:976-87. [PMID: 34448069 DOI: 10.1007/s00535-021-01819-7] [Reference Citation Analysis]
53 Domenis R, Marino M, Cifù A, Scardino G, Curcio F, Fabris M. Circulating exosomes express α4β7 integrin and compete with CD4+ T cells for the binding to Vedolizumab. PLoS One 2020;15:e0242342. [PMID: 33180848 DOI: 10.1371/journal.pone.0242342] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
54 Zhou Z, Zhang Y, Yang X, Pan Y, Li L, Gao C, He C. Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn’s Disease. Front Immunol 2022;13:865968. [DOI: 10.3389/fimmu.2022.865968] [Reference Citation Analysis]